Zepbound is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist ...

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the U.S. Food and Drug Administration ...

Millions of Americans taking injectable weight-loss drugs like semaglutide face a familiar daily routine: find a time to ...

The FDA issued 25 warning letters to telehealth companies last month over misleading claims about compounded versions of ...

An FDA advisory committee has voted by a majority to recommend broader access to certain peptides. Peptides are short chains ...

In two new phase 3 clinical trials, the experimental GLP-1 drug also improved blood sugar, heart health metrics, and ...

Add Yahoo as a preferred source to see more of our stories on Google. The FDA on Thursday said it would exclude the active ingredients in popular GLP-1 weight loss drugs from its 503B list, which ...

The U.S. Food and Drug Administration (FDA) has approved a new weight loss pill from drugmaker Eli Lilly, marking the second GLP-1 in pill form to hit the market in recent months. On Wednesday, April ...

People searching for an affordable way to lose weight with a GLP-1 drug may come across products marketed as “GLP-1 patches” online. They’re advertised as helping to reduce cravings, control appetite ...

Retatrutide isn't supposed to be everywhere. Touted as the next generation in the GLP-1 craze, it's an experimental weight-loss drug that is not authorized outside of clinical trials. The Food and ...

June 16 (Reuters) - The U.S. Food and Drug Administration issued 25 warning letters to telehealth companies for marketing false and misleading claims about compounded versions of Eli Lilly (LLY.N), ...